PMC:7296049 / 26863-27581 JSONTXT

{"target":"https://pubannotation.org/docs/sourcedb/PMC/sourceid/7296049","sourcedb":"PMC","sourceid":"7296049","source_url":"https://www.ncbi.nlm.nih.gov/pmc/7296049","text":"Figure 5 Dl-3-n-butylphthalide (NBP) suppresses astrocytes regeneration after 2VO. (A) Representative images of GFAP (red) and BrdU (green) immunofluorescence double labeling in corpus callosum at 2 weeks and 4 weeks after 2VO. Bar = 50 μm. Typical double-labeled areas are magnified (n = 3 in each group). (B) The number of GFAP+/BrdU+ cells in corpus callosum. *p \u003c 0.05, ***p \u003c 0.001, the model group vs. the sham group; ##p \u003c 0.01, ###p \u003c 0.001, the NBP60 group or NBP120 group vs. the model group; $$p \u003c 0.01, the NBP60 group vs. NBP120 group; \u0026\u0026\u0026p \u003c 0.001, the model group sacrificed at 2 weeks vs. the model group sacrificed at 4 weeks. Values are expressed as mean ± SD. GFAP, glial fibrillary acidic protein.","divisions":[{"label":"label","span":{"begin":0,"end":8}}],"tracks":[]}